Management of Uncontrolled Hypertension in Complex Patients

Introduction to Guideline-Based Management

The European Society of Cardiology recommends discontinuing prazosin and optimizing diuretic therapy with a thiazide-like diuretic, and adding an ACE inhibitor or ARB as the cornerstone of therapy for patients with CKD stage 4, heart failure with reduced ejection fraction, and diabetes 1, 2
The American Heart Association suggests that hydrochlorothiazide is inferior to thiazide-like diuretics in resistant hypertension, and recommends substituting a thiazide-like diuretic for hydrochlorothiazide when blood pressure remains uncontrolled 2

The European Society of Cardiology recommends adding a calcium channel blocker as the second agent, which provides complementary vasodilation and is particularly effective in combination with RAS blockers 1, 3
The American College of Cardiology suggests switching hydrochlorothiazide to chlorthalidone or indapamide, as these thiazide-like diuretics are more effective in CKD and resistant hypertension 2
The European Society of Cardiology recommends continuing spironolactone as the fourth agent, which is the preferred add-on for resistant hypertension and is particularly beneficial in heart failure with reduced ejection fraction 1, 2

The European Society of Cardiology recommends checking serum potassium and creatinine within 1-2 weeks after initiating ACE inhibitor/ARB and continuing spironolactone, as the combination significantly increases hyperkalemia risk, especially with CKD stage 4 1, 4
The American Heart Association suggests monitoring for acute kidney injury, particularly watching for creatinine increases >30% from baseline, which may indicate bilateral renal artery stenosis or volume depletion 4

The European Society of Cardiology recommends that ACE inhibitors or ARBs are mandatory in heart failure with reduced ejection fraction to reduce mortality, and beta-blockers should be added once blood pressure is controlled 1, 4
The American College of Cardiology suggests that spironolactone is particularly beneficial in heart failure with reduced ejection fraction, providing mortality benefit beyond blood pressure reduction 1
The European Society of Cardiology recommends targeting blood pressure is 120-129 mmHg systolic if tolerated, as the 2024 ESC guidelines recommend this intensive target for CKD patients with eGFR >30 mL/min/1.73 m² 1

The European Society of Cardiology recommends not continuing prazosin as part of resistant hypertension management—it is not evidence-based and delays implementation of proven therapies 1, 2
The American Heart Association suggests not using hydrochlorothiazide in resistant hypertension or CKD stage 4—switch to chlorthalidone or indapamide, or use a loop diuretic 2
The European Society of Cardiology recommends not combining ACE inhibitors with ARBs—it increases adverse effects without additional benefit 1, 4